Spyre Therapeutics (SYRE) Common Equity (2015 - 2026)

Spyre Therapeutics (SYRE) has 12 years of Common Equity data on file, last reported at $670.8 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 39.0% year-over-year to $670.8 million; the trailing twelve-month figure through Mar 2026 stood at $670.8 million (up 39.0% YoY), and the FY2025 full-year result was $715.2 million, up 38.13% from the prior year.
• Common Equity for Q1 2026 stood at $670.8 million, down from $715.2 million in the prior quarter.
• Across five years, Common Equity topped out at $715.2 million in Q4 2025 and bottomed at -$245.4 million in Q3 2023.
• The 5-year median for Common Equity is $184.0 million (2023), against an average of $245.9 million.
• The widest annual swing landed in 2023, when Common Equity slumped 463.26%; it then surged 352.48% in 2024.
• A 5-year view of Common Equity shows it stood at $50.3 million in 2022, then jumped by 265.8% to $184.0 million in 2023, then jumped by 181.39% to $517.8 million in 2024, then surged by 38.13% to $715.2 million in 2025, then retreated by 6.21% to $670.8 million in 2026.
• The last three Common Equity figures came in at $670.8 million (Q1 2026), $715.2 million (Q4 2025), and $455.1 million (Q3 2025), per Business Quant data.

Peer Comparison